SCHEMBL5736802

SCHEMBL5736802

CNCc1ccc(NC(=O)c2c[nH]c3c2C(=O)CCCC3)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 3/20 0.41
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
HRH3 Q9Y5N1 1/20 0.38
TP53 P04637 1/20 0.36
ADORA2A P29274 1/20 0.36
NHERF1 O14745 1/20 0.36
MAPT P10636 4/20 0.36
KMT2A Q03164 2/20 0.35
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
PARP1 P09874 1/20 0.34
ALDH1A1 P00352 2/20 0.34
ALK Q9UM73 1/20 0.34
AVPR1A P37288 1/20 0.34
AVPR1B P47901 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5734297 0.99 CFTR (0.40) CFTRROCK2ROCK1HRH3TP53
SCHEMBL5734447 0.88 CFTR (0.39) CFTRROCK2ROCK1HRH3TP53
SCHEMBL5736211 0.88 CFTR (0.39) CFTRROCK2ROCK1HRH3TP53
SCHEMBL5733326 0.88 CFTR (0.41) CFTRROCK2ROCK1HRH3TP53
SCHEMBL4900361 0.86 PARP1 (0.42) NHERF1PARP1
SCHEMBL7366047 0.85 ROCK2 (0.42) CFTRROCK2ROCK1TP53MAPT
SCHEMBL5733698 0.85 KLKB1 (0.44) CFTR
SCHEMBL5734252 0.84 HDAC1 (0.39) CFTRROCK2ROCK1HRH3NHERF1
SCHEMBL5733659 0.84 RET (0.39) CFTRROCK2ROCK1HRH3TP53
SCHEMBL5735503 0.84 CFTR (0.39) CFTRROCK2ROCK1HRH3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1019372-B1 FUSED PYRROLECARBOXAMIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORP (US) 2006-04-05 EP claimed
US-20030153754-A1 Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE 2003-08-14 US claimed
EP-1019372-A1 NOVEL FUSED PYRROLECARBOXAMIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 2000-07-19 EP claimed
WO-1997026243-A1 NOVEL FUSED PYRROLECARBOXAMIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1997-07-24 WO claimed
US-20030153754-A1 Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE 2003-08-14 US disclosed
US-20030153754-A1 Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE 2003-08-14 US disclosed
US-6080873-A Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands NEUROGEN CORPORATION (US) 2000-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030153754-A1 Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands GABRB1, GABRB3, GABRB2 CFTR 3215/4885ROCK2 4104/4885ROCK1 3691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.